Epidarex Capital Creates Nodthera Limited

A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease   Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome. Nodthera is based…

More

Selvita to present at the Annual BIO International Convention 2016

Krakow, 27 May 2016 – Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, will participate and present at the upcoming Annual BIO International Convention, taking place on June 6-9, 2016, at the Moscone Center in San Francisco, USA.   The presentation will be held…

More

Selvita enjoys 36% business growth in Q1 2016

Krakow, Poland – May 16, 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has generated strong revenue growth in the first quarter of 2016. Net sales revenues (excluding grants) amounted to PLN 11.4 MM, as compared to PLN 8.4 MM in Q1 2015, indicating dynamics…

More

Selvita enjoys strong growth in 2015

Krakow, Poland – March 23, 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has reported another year of a double digit revenue growth.   In 2015, the company has enjoyed strong growth of revenues, which amounted to PLN 55.7 MM, compared to PLN 41.3 MM…

More